What is Lassen Therapeutics?
Lassen Therapeutics is a biopharmaceutical company dedicated to creating novel medicines for serious diseases. Leveraging advanced antibody technologies, the company's primary focus is on targeting interleukin-11 to address debilitating conditions such as thyroid eye disease and idiopathic pulmonary fibrosis. Their mission is driven by a commitment to innovation, transparency, and collaboration, aiming to deliver life-improving treatments through a robust pipeline of breakthrough therapeutics.
How much funding has Lassen Therapeutics raised?
Lassen Therapeutics has raised a total of $85M across 1 funding round:
Series B
$85M
Series B (2023): $85M with participation from Frazier Life Sciences Management, Longitude Capital, Alta Partners, Longwood Capital, BVF Partners, and Catalio Capital Management
Key Investors in Lassen Therapeutics
Frazier Life Sciences Management
Frazier Life Sciences is a venture capital firm specializing in early-stage biotech, managing over $5.3 billion in capital and supporting the creation of novel therapeutics through flexible investment strategies and active partnership.
Longitude Capital
Longitude Capital is a healthcare-focused venture capital firm that invests in biotechnology, medical technology, and health solutions companies, providing sector expertise and capital to help innovators scale and improve patient care.
Alta Partners
Alta Partners is a firm providing comprehensive resources for medical billing, physician practice management, and healthcare consulting, aimed at maximizing practice profitability.
What's next for Lassen Therapeutics?
The substantial enterprise-level funding, including the recent major strategic investment, positions Lassen Therapeutics for accelerated development and potential commercialization of its pipeline. This capital infusion is expected to fuel further research and clinical trials, enabling the company to advance its novel antibody-based therapies. The strategic nature of the recent financing suggests strong validation from key industry players, potentially paving the way for future partnerships and market entry.
See full Lassen Therapeutics company page
